Scholarlink

Background <p>Pediatric allergic rhinitis (AR) caused by house dust mite (HDM) is common and may be treated with subcutaneous allergen immunotherapy (SCIT). However, the optimal maintenance dose in children remains unclear.</p> Methods <p>We conducted a&#xa0;cross-sectional comparative study among pediatric patients treated with low-dose (50 AU) versus standard-dose (500 AU) HDM SCIT. The Total Nasal Symptom Score (TNSS) and Total Medication Score (TMS) were assessed.</p> Results <p>Among 71&#xa0;patients, 32&#xa0;received low-dose and 39&#xa0;received standard-dose SCIT. The two groups had comparable TNSS and TMS (TNSS: 5.59 vs. 5.35; TMS: 1.68 vs. 1.23, respectively).</p> Conclusion <p>Low-dose HDM SCIT may provide symptom control comparable to standard-dose SCIT in children, with potential for fewer systemic reactions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Low-dose subcutaneous immunotherapy for pediatric house dust mite allergy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月22日

查看全文
  • Yehonatan Pasternak,
  • Iris Greenbaum,
  • Shirley Sarig Epstein,
  • Yoram Faitelson,
  • Avi Beigelman

摘要

Background

Pediatric allergic rhinitis (AR) caused by house dust mite (HDM) is common and may be treated with subcutaneous allergen immunotherapy (SCIT). However, the optimal maintenance dose in children remains unclear.

Methods

We conducted a cross-sectional comparative study among pediatric patients treated with low-dose (50 AU) versus standard-dose (500 AU) HDM SCIT. The Total Nasal Symptom Score (TNSS) and Total Medication Score (TMS) were assessed.

Results

Among 71 patients, 32 received low-dose and 39 received standard-dose SCIT. The two groups had comparable TNSS and TMS (TNSS: 5.59 vs. 5.35; TMS: 1.68 vs. 1.23, respectively).

Conclusion

Low-dose HDM SCIT may provide symptom control comparable to standard-dose SCIT in children, with potential for fewer systemic reactions.